MedPath

Revisiting Omental Transposition in Locally Advance and Locally Recurrent Breast Cancer

Completed
Conditions
Survival Rate
Registration Number
NCT03052621
Lead Sponsor
Queen Sirikit Centre for Breast Cancer
Brief Summary

Locally advance breast cancer and extensive locoregional recurrence are still considered as complexity of reconstruction. Although previous studies concluded that omental transposition was considerably indicated in poor vascularity in irradiated tissue, secondary infection and large defect become the obstacles of local tissue flaps. While some centres showed the excellent healing of omental transposition. Meanwhile, many studies showed the preferable outcome in escalating radiotherapy in term of locoregional control. In the investigators' institute, omental transposition in breast cancer has been developed for twenty years. The only institute in Thailand enhanced using this procedure in order to closure of large primary breast cancer and chest wall recurrence. This procedure is undertaken by single surgeon (Dr. K.J.). The investigators' protocol of omental transposition is including preoperative chemotherapy, preoperative accelerated radiation up to 80 Gy, approval of breast cancer centre committee, and meticulous wound care including vacuum assisted wound dressing, non-adhesive dressing. As a result, survival time could be improved.

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
Female
Target Recruitment
40
Inclusion Criteria
  • The patients with omental transposition operation within King Chulalongkorn Memorial Hospital
  • More than 18 years of age
Exclusion Criteria
  • The patients with refusal

Study & Design

Study Type
OBSERVATIONAL
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Survival time22 years
Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (1)

Queen Sirikit Centre for Breast Cancer

🇹🇭

Bangkok, Thailand

Queen Sirikit Centre for Breast Cancer
🇹🇭Bangkok, Thailand

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.